Supervivencia de pacientes con cáncer de mama y cirugía conservadora / Survival in Patients with Breast Cancer and Conservative Surgery

Introducción: En la actualidad la cirugía conservadora, más que una opción en el tratamiento quirúrgico del cáncer de mama, es la técnica quirúrgica de elección. Objetivo: Caracterizar la supervivencia de los pacientes con cáncer de mama operados con cirugía conservadora. Métodos: Se realizó un estudio multicéntrico, retrospectivo descriptivo de corte longitudinal, en el Hospital Universitario Clínico Quirúrgico "Arnaldo Milián Castro" y el oncológico "Celestino Hernández Robau", ambos de la ciudad de Santa Clara provincia Villa Clara, en el período comprendido desde enero del 2011 hasta diciembre del 2020. Resultados: La supervivencia global de los pacientes con cáncer de mama y cirugía conservadora en aquellos que presentaron eventos (fallecidos) fue mayor en los portadores de carcinoma ductal infiltrante con 9,3 años. En el caso del estadio tumoral predominó la supervivencia en aquellos pacientes que estaban en estadios Ia y IIa con 9,8 y 9,1 años, respectivamente. Según la inmunohistoquímica, el subtipo molecular con mejor supervivencia global fue el Luminal B con 9,2 años. En cuanto al tratamiento definitivo aplicado presentaron mayor supervivencia global aquellos pacientes que recibieron esquemas de quimioterapia+ radioterapia+ hormono terapia y quimioterapia+ radioterapia con 9,4 y 8,8 años, respectivamente. Conclusiones: Existe una mayor supervivencia global en aquellos pacientes con carcinoma ductal infiltrantes (NOS), estadios tumorales Ia y IIa, con subtipo molecular Luminal B según inmunohistoquímica y con tratamientos definitivos de quimioterapia+ radioterapia+ hormonoterapia(AU)

Introduction: Nowadays, conservative surgery, rather than an option for the surgical treatment of breast cancer, is the surgical technique of choice. Objective: To characterize the survival of patients with breast cancer operated on with conservative surgery. Methods: A multicenter, retrospective, descriptive and longitudinal study was carried out at Hospital Universitario Clínico Quirúrgico "Arnaldo Milián Castro" and "Celestino Hernández Robau" oncologic hospital, both in the city of Santa Clara, Villa Clara Province, in the period from January 2011 to December 2020. Results: The overall survival of patients with breast cancer and conservative surgery in those who presented events (died) was higher in those with infiltrating ductal carcinoma, accounting for 9.3 years. In the case of tumor stage, survival was predominant in those patients with stages IA and IIA, accounting for 9.8 and 9.1 years, respectively. Concerning immunohistochemistry, the molecular subtype with the best overall survival was Luminal B, accounting for 9.2 years. Regarding the applied definitive treatment, those patients who received chemotherapy-radiotherapy-hormone therapy and chemotherapy-radiotherapy schemes presented better overall survival, accounting for 9.4 and 8.8 years, respectively. Conclusions: Overall survival is higher in patients with infiltrating ductal carcinoma (not otherwise specified), tumor stages IA and IIA, molecular subtype Luminal B according to immunohistochemistry, and definitive treatments with chemotherapy, radiotherapy, hormone therapy scheme(AU)

Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report / Angiossarcoma em mama previamente irradiada em paciente portadora da síndrome de Li-Fraumeni. Um relato de caso

CONTEXT: Li-Fraumeni syndrome is a rare disease with an autosomal dominant inheritance pattern and high penetrance that defines a 50% chance of developing cancer before the age of 30 years, including cases of breast sarcoma. Patients with this syndrome who require radiotherapy have an increased risk of developing secondary malignancies including angiosarcomas. CASE REPORT: This was a case report on a female patient with Li-Fraumeni syndrome. In October 2005, she was diagnosed with invasive ductal carcinoma of the right breast and underwent sectorectomy. She then received chemotherapy and adjuvant radiotherapy. Trastuzumab and tamoxifen were also part of the treatment. She recently sought care at our hospital, complaining of hyperemia and nodulation in the right breast, and underwent surgical resection that revealed epithelioid angiosarcoma. CONCLUSIONS: When genetic predisposition due to Li-Fraumeni syndrome is documented, the therapy should be adapted so as to minimize the risk. Thus, conservative surgical treatments should be avoided and mastectomy without radiation should be prioritized. In cases in which use of radiotherapy is justified, patients should be followed up intensively. .

CONTEXTO: A síndrome de Li-Fraumeni é doença rara que apresenta padrão de herança autossômica dominante e alta penetrância, definindo possibilidade de 50% no desenvolvimento de neoplasias antes dos 30 anos, incluindo nesses casos os sarcomas em mama. Pacientes portadoras dessa síndrome que requerem tratamento radioterápico têm risco aumentado de desenvolver neoplasias secundárias, incluindo os angiossarcomas. RELATO DE CASO: Este é um relato de caso de paciente feminina, portadora da síndrome de Li-Fraumeni. Em outubro de 2005, ela teve diagnóstico de carcinoma ductal invasor da mama direita, sendo submetida à setorectomia. Recebeu quimioterapia e radioterapia adjuvante; trastuzumabe e tamoxifeno também fizeram parte do tratamento. Recentemente, procurou atendimento em nosso serviço, com queixa de hiperemia e nodulação em mama direita, e foi submetida a ressecção cirúrgica que revelou angiossarcoma epitelioide. CONCLUSÕES: Quando a predisposição genética da síndrome de Li-Fraumeni está documentada, devese adequar a terapêutica a fim de minimizar riscos, evitando tratamentos cirúrgicos conservadores e priorizando a mastectomia sem radioterapia. Nos casos em que se justifica o uso de radioterapia, os pacientes devem ser acompanhados de forma intensiva. .

Correlation of clinico-pathologic and radiologic parameters of response to neoadjuvant chemotherapy in breast cancer.

CONTEXT: As of today, there is no validated standard method to assess clinical response of breast cancer to neo- adjuvant chemotherapy (NACT). Some centers use clinical dimensions while others use radiological measurements to evaluate response according to RECIST criteria. AIMS: The aim was to correlate and compare the clinical, radiological, and pathological parameters for assessing the tumor response in patients of breast cancer receiving NACT. SETTINGS AND DESIGN: Single institution, prospective nonrandomized study conducted over a 2-year period. MATERIALS AND METHODS: Patients with diagnosed breast cancer were assessed for response to NACT prior to surgery using clinical and radiological techniques. This was correlated with pathological reponse which was assessed by measuring gross dimensions and Miller-Payne grading of response to chemotherapy. STATISTICAL ANALYSIS USED: Spearman’s rho nonparametric. RESULTS: Fifty two patients completed the evaluation (out of 313 cases of ca breast treated during the same period) with a median age of 52.5 years. We noted a 26.9% clinical complete response (CR) and 19.2% had pathological CR. Clinical evaluation had a sensitivity and specificity of 73.5% and 88.5% respectively compared to 14.2% and 100% respectively for radiological assessment. CONCLUSIONS: Clinical assessment of response to NACT shows a higher sensitivity compared to radiological assessment. However the overall low sensitivity and specificity rates of clinical assessment mandate a search for a better method of evaluation.

Câncer de mama estádio inicial e radioterapia: atualização / Early stage breast cancer and radiotherapy: update

O câncer de mama é a neoplasia maligna mais frequente entre as mulheres. A escolha terapêutica depende do estádio clínico da doença, das características anatomopatológicas, idade, entre outros. O objetivo do presente estudo é apresentar uma atualização dos conceitos e definições da radioterapia (RT) no tratamento conservador do câncer de mama estádio inicial, enfatizando as indicações, contraindicações, dose e fracionamento da RT (esquema clássico, hipofracionado e irradiação parcial da mama), RT adjuvante no carcinoma ductal in situ (CDIS), irradiação das cadeias linfonodais e relação da RT com preditores moleculares de recorrência. Foram utilizadas as bases de dados MEDLINE, SciELO e Cochrane para a seleção dos principais artigos disponíveis sobre a temática proposta. A RT adjuvante tem um papel definido na abordagem das pacientes com câncer da mama submetidas à terapia cirúrgica conservadora. Em pacientes selecionadas, podem-se empregar esquemas de RT hipofracionada ou irradiação parcial das mamas. Todas as pacientes com CDIS devem receber RT adjuvante. Não se sabe a correlação do papel da RT com preditores moleculares de recorrência local e sistêmica.

Breast cancer (BC) is the most common malignancy among women. Therapeutic options are based on disease staging, histopathological characteristics, age, and others. The objective of the present study is to carry out an update of the concepts and definitions of radiotherapy (RT) in conservative treatment of early-stage breast cancer, with emphasis on indications, contraindications, RT dose fractionation schedules (classic, hypofractionated and partial breast irradiation), adjuvant RT in ductal carcinoma in situ (DCIS) and molecular predictors of recurrence. MEDLINE, SciELO and Cochrane databases were used for article selection. Adjuvant RT is indicated for patients with BC who underwent conservative breast surgery. In selected patients, hypofractionated or partial breast irradiation can be used. Adjuvant RT should be provided for all patients with DCIS. The correlation of RT and molecular predictors of local and systemic recurrence are not yet well-known.

Síndrome adyuvante por implante de protesis mamarias de silicón (siliconosis): ¿una condición emergente? / Adjuvant syndrome due to silicone breast prosthesis implant (siliconosis): an emergent condition?

Los implantes mamarios de silicona se han asociado con una variedad de condiciones médicas que aparecen en coincidencia con su implantación; ello constituye la emergencia de una nueva y poco conocida patología de la modernidad. Más del 87% de los enfermos sintomáticos, presentan neuropatía desmielinizante y axonal, comprobada en la biopsia de nervio y músculo, mientras que aproximadamente el 22%-25% tienen evidencia de enfermedad tiroidea autoinmune. Un pequeño porcentaje del 10%-12%, presentan enfermedad desmielinizante primaria del sistema nervioso: esclerosis múltiple diagnósticada mediante resonancia magnética y estudios de líquido cefalorraquideo. Otros presentan condiciones inmunológicas diversas como síndrome de fibromialgia, tiroiditis de Hashimoto, polimiositis, dermatomiositis, lupus eritematoso sistémico, artritis reumatoide, esclerodermia y presencia de autoanticuerpos. Para estos pacientes sintomáticos se propone como diagnóstico unitario un síndrome adyuvante por implante de prótesis mamarias de silicon. Se presentan los casos de dos pacientes ilustrativos.

Silicone breast prosthesis has been associated with a variety of medical conditions or autoimmune diseases, which has coincidental relation with the implants insertion; it's loomed as a new and unknown pathology of the modern times. More than 87% of symptomatic patients developed demyelination axonal neuropathy demonstrated by nerve and muscle biopsy; 22% to 25% have evidence of autoimmune thyroid disease. An a small group of patients (10%-12%) have primary central nervous system demyelination disease as. multiple selerosis. The diagnosis of multiple selerosis was corroborated by magnetic resonance imaging and cerebrospinal fluid analysis. Also, an other wide spectrum of immunological diseases have been observed, such as fibromyalgia. Hashimoto's, polymyositis, dermatomyositis, lupus erythematosus, rheumatoid arthritis, scleroderma, and the presence of autoantibodies. Finally, for symptomatic patients, an adjuvant syndrome of silicone breast prosthesis or implant is proposed as a unitary diagnosis. The authors presented two patients whom illustrated this entity.

Metástasis coroidea como primera manifestación de recaída sistémica en el cáncer de mama / Choroid metastases are a first manifestation of system relapse in breast cancer

La metástasis coroidea es una entidad poco frecuente y está asociada usualmente a un mal pronóstico, siendo el cáncer de mama su principal causa. Se presenta el caso de un paciente femenino de 47 años de edad con antecedente de cáncer de mama estadio IIIA diagnosticado y tratado en 1998, permaneciendo libre de enfermedad locorregional y a distancia hasta julio de 2005 cuando presenta disminución de la agudeza visual basados en los test clínicos se le diagnosticó metástasis coroidea en ojo derecho. Inicia tratamiento local y sistémico con evolución satisfactoria y remisión completa de la lesión corroborada por estudios complementarios.

The choroid metastasis, are not frequent in intraocular malignant tumors, the breast cancer, is the primary tumor more frequently responsible for ocular metastases. These reports describe a feminine 47 years old diagnosed with infiltrating ductal carcinoma of her right breast classified how state III. A treated in 1998, she was free of disease until July of 2005, she complained of diminished visual acuity of her right eye. Based on the clinical and test outcomes the following diagnosis was reached: Choroid metastasis in the right eye, from a known primary tumor. The patient started treatment local and systemically chemotherapy with excellent response.

Micro-pixe analysis in invasive ductal carcinoma tissues after treatment of astaxanthin

Trace elements play an important role in a number of biological processes. Astaxanthin [ASX], a carotoid pigment found in certain marine plant and animals, has shown anti cancer and anti free radical properties. This work intended to understand the effect of Astaxanthin in breast cancer [invasive ductal carcinoma, IDC] by using micro-pixe method. For this aim the concentration of trace elements were compared in healthy, cancerous and cancer treated with astaxanthin in the breast and liver tissues of breast cancer bearing mice, using proton induced X-ray emission [PIXE]. Proton induced X-ray emission [PIXE] was used in a study intending to compare the concentration of trace elements in breast and liver tissues of mice bearing tumor, three groups of mice: healthy, cancerous, and cancerous treated by astaxanthin, were considered. Astaxanthin was supplied from Research Institute of women, Alzahra University. Comparing the untreated tumor tissue, treatment with Astaxanthin significantly decreased the amount Fe, P, S, and Ca elements level in tumor tissue of the breast cancer. It is also found that the concentrations of those elements in liver of the untreated mice and the liver of treated mice with astaxanthin were fairly equal. Astaxanthin significantly decrease the accumulation of elements in the site of tumor, and caused the breast cancer cell membrane to lose their desire to collect the elements from healthy tissues. The micro-pixe technique could calculate elemental concentrations in tissues. Changes in metallic elements may affect microenvironment and cell functions, which might led lead to cell degeneration or death, the results shows that astaxanthin reduces vital element concentration in tumor site, thus it could be used as an anti tumor agent

Tratamento conservador do câncer de mama T2 (≥ 4 cm) e T3 por quimioterapia neoadjuvante, quadrantectomia, braquiterapia com alta taxa de dose como reforço de dose, teleterapia complementar e quimioterapia adjuvante: análise de controle local e sobrevida global / Breast conserving treatment of breast carcinoma T2 (≥ 4 cm) and T3 by neoadjuvant chemotherapy, quadrantectomy, high dose rate brachytherapy as a boost, external beam radiotherapy and adjuvant chemotherapy: local control and overall survival analysis

OBJETIVO: Avaliar o tratamento de carcinomas de mama T2 (≥ 4 cm) e T3, por quimioterapia neoadjuvante, quadrantectomia e braquiterapia com alta taxa de dose como reforço de dose (boost), radioterapia complementar e quimioterapia adjuvante, quanto ao controle local e sobrevida global.MATERIAL E MÉTODO: Trata-se de estudo clínico prospectivo descritivo que avaliou 88 pacientes com idade entre 30 e 70 anos, portadoras de carcinoma ductal infiltrante, nos estádio clínico IIb e IIIa, responsivas à quimioterapia neoadjuvante, tratadas entre junho de 1995 e dezembro de 2006. A resposta do tumor foi avaliada por método clínico antes e após três ou quatro ciclos de quimioterapia contendo antracíclicos. O seguimento mediano foi de 58 meses. Sobrevida global e controle local foram analisados segundo o método de Kaplan-Meier. RESULTADOS: O controle local e a sobrevida global em cinco anos foram de 90% e 73,5%, respectivamente. CONCLUSÃO: O controle local e a sobrevida global são comparáveis aos observados em outras formas terapêuticas.

OBJECTIVE: To assess the treatment of breast cancer T2 (≥ 4 cm) and T3 through neoadjuvant chemotherapy, quadrantectomy and high dose rate brachyterapy as a boost, complementary radiotherapy and adjuvant chemotherapy, considering local control and overall survival. MATERIAL AND METHOD: This clinical prospectivedescriptive study was based on the evaluation of 88 patients rangingfrom 30 to 70 years old, with infiltrating ductal carcinoma, clinical stage IIb and IIIa, responsive to the neoadjuvant chemotherapy, treated from June/1995 to December/2006. Median follow-up was 58 months. Using clinical methods the tumor was evaluated before and after three or four cycles of chemotherapy based on antraciclins. Overall survival and local control were assessed according to Kaplan-Meier methodology. RESULTS: Local control and overall survival in five years were 90% and 73.5%, respectively. CONCLUSION: Local control and overall survival were comparable to other forms of treatment.

Postmastectomy radiation and survival in patients with breast cancer.

PURPOSE: To analyze the impact of postmastectomy radiotherapy on locoregional control and overall survival in patients with carcinoma breast. MATERIALS AND METHODS: Between 1995 and 2000, 688 patients of carcinoma breast were analyzed. Out of these, 608 received postmastectomy radiotherapy and 80 patients were not given any radiation therapy. At a median follow-up of 67 months, the outcomes studied were locoregional recurrence (LRR), distant metastases, disease-free survival (DFS) and overall survival (OS) using univariate and multivariate analyses. RESULTS: The frequency of LRR with or without distant metastases was 8.5%, and distant metastases was seen in 18.7% of patients. On univariate analyses, factors affecting LRR were age < 40 years (0.019), tumor stage ( P = 0.001 ), grade ( P = 0.027 ), pathological nodal status ( P ), deep resection plane (0.041), ER/PR status ( P = 0.032 ) and postmastectomy radiation therapy (PMRT) ( P ). DFS rate was 69% at 5 years. Factors affecting distant metastases were age < 40 years (0.005), tumor stage ( P ), grade ( P = 0.0007 ), pathological nodal status ( P ), extra capsular extension (ECE) ( P = 0.002 ), hormonal therapy ( P ) and PMRT ( P ). The OS rate was 81% at 5 years. Factors affecting OS were tumor stage ( P ), grade ( P = 0.0001 ), pathological nodal status ( P ), ECE ( P = 0.002 ) ER/PR status ( P = 0.008 ), hormonal therapy ( P = 0.001 ) and PMRT ( P = 0.004 ). On multivariate analysis, factors affecting LRR were age ( P = 0.001 ), tumor stage ( P = 0.021 ), deep resection plane (0.003), ECE ( P = 0.022 ) and PMRT ( P = 0.047 ). Factors affecting distant metastases were menopause ( P = 0.044 ), grade ( P = 0.012 ), ECE ( P = 0.017 ) and PMRT ( P = 0.012 ). Factors affecting OS were menopausal status ( P = 0.017 ), tumor stage ( P = 0.029 ), pathological nodal status ( P = 0.011 ) and PMRT ( P = 0.002 ). CONCLUSION: PMRT improves LRR as well as OS in patients with carcinoma breast. Other factors of prognostic importance were menopausal status, tumor stage and pathological nodal status.

¿Es curable el cáncer de mama en etapa precoz?: Resultados del tratamiento combinado con cirugía, radioterapia y quimioterapia / Treatment results of early breast cancer: A retrospective review

Background: Breast cancer will develop in one out of ten women during their lifetime. Early diagnosis has increased in recent years. Aim: To describe a population of women with breast cancer stage T1N0M0. To analyze radiation therapy toxicity and to evaluate treatment results. Material and methods: Retrospective review of the medical records of 125 women (aged 35 to 80 years) with breast cancer T1N0M0, that were treated between January 1997 and May 2004, with breast conserving surgery and postoperative radiation therapy at an oncology center. Patients lost from follow up were contacted by telephone. Results: An abnormal screening mammography was the reason for consult in 62 percent of cases. The average tumor size was 11.6 mm. Tumors detected with screening mammogram were smaller than those detected on physical exam. The most common radiotherapy toxicity was erithema, which was severe in 2.5 percent of cases. No patient had to stop the radiation treatment due to toxicity. One patient developed arm edema. Tamoxifen was prescribed for 5 years to 80 percent of patients and 17 patients received chemotherapy. After an average follow up of 40 months, no patient has developed local breast relapse, three patients developed contralateral breast cancer and three developed distant metastasis. Two patients died from breast cancer. Disease free survival was 95 percent. Conclusions: Radiotherapy was well tolerated and had excellent local control. Screening mammography detects small tumors. Survival is excellent for early stage breast cancer.

Cáncer de seno en la Clínica San Pedro Claver de Bogotá, 2004 / Breast cancer in the Pedro Claver hospital in Bogotá, 2004

OBJETIVO: Revisar los casos nuevos de cáncer de seno atendidos durante el año 2004 en la Clínica San Pedro Claver, Bogotá, Colombia. MATERIAL Y MÉTODOS: La captación de las pacientes se hizo a través de la junta de seno, actividad a la cual asisten todas las pacientes nuevas de este servicio. Para garantizar la inclusión de la totalidad de ellas, además se realizó búsqueda activa de los casos entre las pacientes hospitalizadas, consulta externa, registros de programación de cirugía y reportes de patología. Los datos fueron registrados en un archivo Excel y evaluados mediante el programa EPIINFO. RESULTADOS: Se encontraron 220 casos de cáncer de mama. La edad promedio fue 59 años, el 18 por ciento tenía menos de 50 años. El carcinoma ductal infiltrante con el 84,1 por ciento de los casos fue el tipo histológico más frecuente. La distribución según estadíos concentró el mayor número de pacientes en los estados 0 al II en el 62,7 por ciento. Los tumores midieron más de 2 centímetros en el 78 por ciento de ellos. El tratamiento quirúrgico se realizó en el 83 por ciento de las pacientes y el de quimioterapia en el 60 por ciento. Sin embargo, en las mujeres mayores de 69 años tanto la cirugía (58,3 por ciento) como la quimioterapia (13,9 por ciento) fueron indicados en proporciones inferiores a las de las mujeres con menor edad (p<0.05). En el 40,9 por ciento de los casos, se indicó hormonoterapia. CONCLUSIONES: El registro institucional de Cáncer de la Clínica San Pedro Claver permite conocer las características personales, Clínicas y modalidades terapéuticas pertenecientes a los casos nuevos de cáncer de mama atendidas durante el año 2004 en esta institución. La mayoría de los casos corresponden a estados tempranos. Sin embargo, se debe continuar en el empeño de detectar un mayor número de lesiones no palpables. Se hace necesario evaluar los tratamientos indicados en las mujeres mayores de 69 años con respecto a lo encontrado en los grupos más jóvenes y la calidad del procedimiento, laboratorio, reporte de los receptores hormonales y la decisión terapéutica que puedan explicar la baja proporción del tratamiento con hormonoterapia.

Acute effects of postmastectomy radiotherapy after immediate TRAM flap reconstruction in breast cancer patients.

OBJECTIVES: To study the acute effects of radiotherapy after mastectomy and immediate transverse rectus abdominis myocutaneous (TRAM) flap reconstruction in breast cancer patients treated at Ramathibodi Hospital. MATERIAL AND METHOD: Between January 2004 and March 2005, ten breast cancer patients (age 32-51 years) were treated with postoperative radiotherapy after mastectomy and immediate TRAM flap reconstruction. Medical records of these patients were retrospectively reviewed. Radiotherapy was delivered to the chest wall and reconstructed TRAM flap using 6-MV x-ray or Cobalt-60. The total dose was 45 to 50.4 Gy delivered in 25 to 28 fractions. Patients were evaluated weekly during the course of radiation and then at 1 and 2 months after treatment completion to determine acute effects or toxicities of radiation. RESULTS: During radiation, 3 patients developed erythema or mild hyperpigmentation of the skin, and 4 developed moderate hyperpigmentation. Three patients who were treated with Cobalt-60 and/or bolus to the chest wall developed skin desquamation (1 dry desquamation, 2 moist desquamation). No patient required a treatment break because of acute side effects. One patient who received chemotherapy after radiation developed recalled moist desquamation. CONCLUSION: Radiotherapy after mastectomy and immediate TRAM flap reconstruction is well tolerated and is not associated with increased acute complication or radiation interruption. The authors have noticed that chemotherapy given after radiation was related to severe skin reaction, so it should be used with caution.

Cáncer de mama y prótesis / Prosthesis and breast cancer

La frecuencia de mujeres con implantes mamarios que desarrollarán cáncer aumentará considerablemente en los próximos años. Se comentan estudios epidemiológicos que relacionan riesgo de cáncer y prótesis. Se presentan 3 casos de pacientes con cáncer de mama e implantes, discutiéndose aspectos relacionados con el diagnóstico, tratamiento y resultados cosméticos de esta asociación aún poco frecuente.

Indicadores de riesgo de recidiva local en el tratamiento conservador del cáncer de mama / Risk indicators of local relapse in the conservative treatment of the breast cancer

Fueron evaluados los posibles factores de riesgo para recidiva mamaria en pacientes con estadio I y II de adenocarcinoma ductal invasor, sometidas a tratamiento conservador. Luego de un seguimiento promedio de 60 meses, se registraron 20 recidivas en 211 pacientes con tratamiento conservador. Sobre un total de 152 pacientes se realizó un análisis estadístico, uni y multivariado, para hallar los factores de significación respecto al riesgo de recidiva. Igual metodología de análisis fue implementada en pacientes pre y postmenopáusicas por separado. Se identificaron dos tipos de factores, aquellos asociados con la agresividad tumoral y los relacionados con la enfermedad residual. Tanto para pacientes premenopáusicas como postmenopáusicas, el factor de riesgo más significativo del primer tipo, fue la invasión vascular. Entre los factores asociados a enfermedad residual. Tanto para pacientes premenopáusicas como postmenopáusicas, el factor de riesgo más significativo del primer tipo, fue la invasión vascular. Entre los factores asociados a enfermedad residual, resultó significativo la presencia de componente intraductal extenso. Los bordes quirúrgicos comprometidos resultaron estadísticamente significativos sólo en pacientes postmenopáusicas.